
Commentary|Videos|February 12, 2025
Improving Clinical Trials Through Inclusion, Access, and Engagement
Fact checked by: Jordyn Sava
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.
Advertisement
Mariam F. Eskander, MD, MPH, assistant professor of surgery and a gastrointestinal surgical oncologist at the Rutgers Cancer Institute, and Coral O. Omene, MD, PhD, an associate professor of medicine, breast medical oncologist, and program director for breast cancer disparities research at Rutgers Cancer Institute, discuss potential long-term, sustainable strategies that teams can implement to ensure clinical trials are more representative of the general population, and how that may differ between academic and community oncology settings.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5




























